Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ GoPro Zooms 34% Higher on Starman Optical Merger and Markiplier Stake; Coherent Climbs 7%, Lumentum Gains... (24/7 Wall St.) +++ GOPRO Aktie +4,65%

ENOVIS Aktie

 >ENOVIS Aktienkurs 
15.9 EUR    -4.8%    (TradegateBSX)
Ask: 16 EUR / 210 Stück
Bid: 15.9 EUR / 210 Stück
Tagesumsatz: 245 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ENOVIS Aktie über LYNX handeln
>ENOVIS Performance
1 Woche: -25,7%
1 Monat: -40,4%
3 Monate: -19,5%
6 Monate: -28,1%
1 Jahr: -39,8%
laufendes Jahr: -30,9%
>ENOVIS Aktie
Name:  ENOVIS CORP.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1940145022 / A3DHHV
Symbol/ Ticker:  C520 (Frankfurt) / ENOV (NYSE)
Kürzel:  FRA:C520, ETR:C520, C520:GR, NYSE:ENOV
Index:  -
Webseite:  https://enovis.com/
Profil:  Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions for musculoskeletal health. Enovis Corporation designs, manufactures, and distributes medical devices and services used across the patient ca..
>Volltext..
Marktkapitalisierung:  1021.83 Mio. EUR
Unternehmenswert:  2194.37 Mio. EUR
Umsatz:  1982.11 Mio. EUR
EBITDA:  322.82 Mio. EUR
Nettogewinn:  -949.4 Mio. EUR
Gewinn je Aktie:  -16.6 EUR
Schulden:  1181.57 Mio. EUR
Liquide Mittel:  10.84 Mio. EUR
Operativer Cashflow:  233.12 Mio. EUR
Bargeldquote:  0.02
Umsatzwachstum:  4.89%
Gewinnwachstum:  -32.92%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel 2 Insider kauften innerhalb der letzten 30 Tage Aktien im Wert von 344.063 Euro.
Suchwörter:  ENOVIS
Letzte Datenerhebung:  05.09.26
>ENOVIS Kennzahlen
Aktien/ Unternehmen:
Aktien: 57.67 Mio. St.
Frei handelbar: 97.56%
Rückkaufquote: -0.1%
Mitarbeiter: 7802
Umsatz/Mitarb.: 0.25 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 83.94%
Bewertung:
KGV: -
KGV lG: 5.73
KUV: 0.56
KBV: 0.81
PEG-Ratio: -0.04
EV/EBITDA: 6.8
Rentabilität:
Bruttomarge: 53.34%
Gewinnmarge: -47.9%
Operative Marge: 3.41%
Managementeffizenz:
Gesamtkaprendite: -25.03%
Eigenkaprendite: -54.25%
>ENOVIS Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
05.09.26 - 07:01
Insiderhandel: Chief Administrative Officer kauft Aktien von Enovis im Wert von 100024 USD (Insiderkauf)
 
Engert, Oliver - Vorstand - Tag der Transaktion: 2026-09-03...
05.09.26 - 07:01
Insiderhandel: Chief Executive Officer kauft Aktien von Enovis im Wert von 249620 USD (Insiderkauf)
 
Mcdonald, Damien - Vorstand - Tag der Transaktion: 2026-09-04...
05.09.26 - 07:01
Insiderhandel: Chief Administrative Officer kauft Aktien von Enovis im Wert von 49947 USD (Insiderkauf)
 
Engert, Oliver - Vorstand - Tag der Transaktion: 2026-09-02...
03.09.26 - 19:45
What Makes Enovis (ENOV) a New Buy Stock (Zacks)
 
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
03.09.26 - 15:03
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors (Business Wire)
 
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the appointment of Barbara Bodem and Elizabeth Mily to its board of directors. “We are delighted to welcome Barbara and Elizabeth as independent directors to our board of directors,” said Athena Countouriotis, M.D., Chair, President, and CEO of Avenzo. “Their proven track records along with their combined deep financial and business development expertise across the life science industry will be invaluable as we continue to advance our pipeline of potentially differentiated oncology therapies. We look forward to benefiting from their insights and leadership as we enter the next phase of our company's growth.” Ms. Bodem is an accomplished business leader and experienced board director with more than 30 years of experience across the healthcare industry. She currently serves on the boards of BioMarin Pharmaceutical, Enovis Corpora...
02.09.26 - 21:15
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition (Zacks)
 
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins....
01.09.26 - 22:45
Enovis drops 17% on binding offer to acquire eCential Robotics (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.09.26 - 13:06
Enovis to acquire eCential Robotics (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.09.26 - 12:48
eCential Robotics Announces Binding Offer from Enovis (PR Newswire)
 
eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn., Sept. 1, 2026 /PRNewswire/ -- eCential Robotics, a leading developer of enabling technologies and surgical robotics, today announced that Enovis™ Corporation (NYSE: ENOV) has......
18.08.26 - 13:06
Former President of DePuy Synthes U.S. Joins Peptilogics Board (Business Wire)
 
Tim Czartoski's appointment reinforces moving beyond the device in orthopedic surgery towards therapeutic treatment of device-related infectionsPITTSBURGH--(BUSINESS WIRE)--#Biopharma--Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device businesses, including successful launches of robotic technology platforms and one of the industry's most advanced knee systems, lends significant value to Peptilogics as it moves towards bringing meaningful innovation to market. Czartoski sees tremendous opportunity in therapeutic solutions that advance or complement current approaches to prosthetic joint infections (PJI) and medical device-related infections (MDRI), complications that have been addressed almost exclusively through device and surgical innovation for more than fifty years. “Infection is the most significant, uns...
07.08.26 - 05:30
Enovis reaffirms 2026 outlook and targets >25% free cash flow conversion as Arvis rollout expands (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.26 - 15:15
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates (Zacks)
 
Enovis (ENOV) delivered earnings and revenue surprises of +8.43% and +0.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
06.08.26 - 12:15
Enovis Corporation beats top-line and bottom-line estimates; reaffirms FY26 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.26 - 12:12
Enovis Announces Second Quarter 2026 Results (GlobeNewswire EN)
 
Dallas, TX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET....
28.07.26 - 15:16
UBS starts medtech coverage, favors Intuitive Surgical and Enovis (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
28.07.26 - 15:12
UBS nimmt Medtech-Sektor unter die Lupe: Intuitive Surgical und Enovis als Favoriten (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.07.26 - 14:03
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th (GlobeNewswire EN)
 
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com....
09.07.26 - 15:03
OrthoArizona Surgeon Performs First Augmented Reality Shoulder Replacement in Arizona (PR Newswire)
 
Utilizing a wearable, self-contained AR system from Enovis, the procedure marks a historic milestone and sets a new standard for surgical accuracy SCOTTSDALE, Ariz., July 9, 2026 /PRNewswire/ -- OrthoArizona, the largest physician-led orthopedic group in the Southwest, announced that Dr.......
07.07.26 - 05:18
Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update (RTTNews)
 
Today's top gainers include Innovative Eyewear, which announced preliminary second-quarter net sales; Seer, following an acquisition proposal; and Orthofix and Enovis, which stand to benefit from CMS reimbursement reversal, among others....
06.07.26 - 17:24
Enovis-Aktie springt nach Rücknahme von Medicare-Erstattungskürzungen (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Um einen Graben zu füllen, muß ein Hügel abgetragen werden. - Sprichwort Armenien
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!